Atopic Dermatitis

Most research into the rare condition is focused on therapies and diagnostics, but investigators say it is important to better understand the disease’s impact on those around the patient.

The new analysis suggests the infections rarely leads to discontinuation in patients with atopic dermatitis.

These new data come as the FDA reviews the new drug application for deucravacitinib which, if approved, would make deucravacitinib the first allosteric tyrosine kinase 2 inhibitor approved for any disease.

Raj J. Chovatiya, MD, PhD, provides an overview of JAK inhibitors and their use in atopic dermatitis treatment.

Alexandra K. Golant, MD; Raj. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss goals of therapy for patients with atopic dermatitis and challenges physicians face in management of the disease.

A new study suggests a close examination of the medical histories of patients with generalized pustular psoriasis can make clear which are most likely to die or be hospitalized in the ICU.

The inflammatory markers and leukocyte profiles detailed in the study had not been previously evaluated in any longitudinal studies.

Despite this, an increased incidence of mild to moderate oral candidiasis was also observed in the pooled data from 8 trials.

Recent research has indicated that photos of skin can be used to assess AD severity.

Investigators believe that the BPDAI may under-estimate overall disease severity in darker skin types.

The study was specific to Olmsted County, Minnesota, and was the first American population-based study examining the association between hidradenitis suppurativa and these various conditions

Though minocycline therapy has been effective in treating acne, it can often leave erythema and hyperpigmentation which can be mitigated via Intense Pulsed Light.

Dr. Christine Rauscher details immunotherapy for seasonal allergies, which affect roughly 20 millions adults in the US

Eric Simpson, MD, MCR, reviews conventional topical and systemic therapy treatment options for the management of atopic dermatitis.

Drs Eric Simpson, Alexandra K. Golant, and Raj J. Chovatiya share their approaches to atopic dermatitis care.

Previous data suggests that lower antioxidant status in early life is associated with allergic status in childhood, which implies that antioxidant use could be beneficial in the management of atopic dermatitis.

The risk of cSCC was significantly higher in patients who received treatment for actinic keratosis.

However, comorbidity risk was believed to be substantially different between the two diseases.

Raj J. Chovatiya, MD, PhD, comments on the impact of atopic dermatitis on the quality of life for patients and their families.

Eric Simpson, MD, MCR; and Alexandra K. Golant, MD, provide an overview of the pathophysiology of atopic dermatitis and detail how to approach an atopic dermatitis diagnosis.

EPSOLAY is the first and only micro-encapsulated benzoyl peroxide topical treatment shown to improve inflammatory lesions associated with rosacea

Double board certified dermatologist Dr. Karan Lal details targeted therapies and surgical treatments for vitiligo and how the condition is perceived by different cultures.

Dr. Brett King returns to discuss the impact of JAK inhibitors in the management of atopic dermatitis.

Dr. Sarah Asch details therapeutic strategies for treating pediatric patients with vitiligo.

Key themes such as a distrust in conventional therapies and non-conventional "cures" with no scientific evidence were observed.